BCR-ABL rearrangements in children with Philadelphia chromosome- positive chronic myelogenous leukemia [PDF]
Blood, 1991 Abstract Leukemia cells from adults with Philadelphia (Ph1)-chromosome positive chronic myelogenous leukemia (CML) have a characteristic molecular rearrangement between the BCR and ABL genes whereby major breakpoint cluster region (Mbcr) exons 2 or 3 are joined to ABL exon II.
I, Aurer, A, Butturini, R P, Gale
openaire +3 more sources
New type of Bcr/Abl junction in Philadelphia chromosome-positive chronic myelogenous leukemia [PDF]
Blood, 1990 A new and rare type of Bcr/Abl junction between exon C3 of the 3′ portion of the Bcr gene and Abl exon 2 has been identified in the leukemic cells of two Ph1-positive chronic myelogenous leukemia patients in chronic phase. This is the fourth type of Bcr/Abl junction so far identified in Ph1-positive hematologic malignancies and is a consequence of an ...
G, Saglio +8 more
openaire +3 more sources
Long circulating lectin conjugated paclitaxel loaded magnetic nanoparticles: a new theranostic avenue for leukemia therapy. [PDF]
PLoS ONE, 2011 Amongst all leukemias, Bcr-Abl positive chronic myelogenous leukemia (CML) confers resistance to native drug due to multi drug resistance and also resistance to p53 and fas ligand pathways.
Abhalaxmi Singh +2 more
doaj +1 more source
Combination of bortezomib and mitotic inhibitors down-modulate Bcr-Abl and efficiently eliminates tyrosine-kinase inhibitor sensitive and resistant Bcr-Abl-positive leukemic cells. [PDF]
PLoS ONE, 2013 Emergence of resistance to Tyrosine-Kinase Inhibitors (TKIs), such as imatinib, dasatinib and nilotinib, in Chronic Myelogenous Leukemia (CML) demands new therapeutic strategies.
Octavian Bucur +7 more
doaj +1 more source
Proliferating status of peripheral blood progenitor cells from patients with BCR/ABL-positive chronic myelogenous leukemia [PDF]
Leukemia, 2001 To investigate the mechanisms behind the leukemic expansion of BCR/ABL-positive chronic myelogenous leukemia (CML), we examined the cell cycle status of hematopoietic progenitor cells from peripheral blood (PB) and bone marrow (BM) of 37 patients with newly diagnosed BCR/ABL-positive CML.
A, Krämer +4 more
openaire +2 more sources
Isolated monocytosis was the flag preceding abnormalities in other parameters of complete blood counts in chronic myeloid leukemia with e1a2 (minor, P190) chimeric transcripts [PDF]
Precision and Future Medicine, 2019 Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm with the molecular hallmark of BCR-ABL1 chimeric transcripts from t(9;22)(q24;q22). In more than 95% of CML, the fusion occurs in the major breakpoint cluster region (M-bcr) of BCR, most ...
Jae Won Yun +5 more
doaj +1 more source
NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR–ABL-positive mice [PDF]
Leukemia, 2011 Although BCR-ABL+ stem cells in chronic myeloid leukemia (CML) resist elimination by targeted pharmacotherapy in most patients, immunological graft-versus-leukemia effects can cure the disease. Besides cytotoxic T cells, natural killer (NK) cells may have a role in immune control of CML.
C I-U, Chen +11 more
openaire +2 more sources
Leukemic infiltration of the ovary as an initial presentation of chronic myeloid leukemia in chronic phase [PDF]
Vojnosanitetski Pregled, 2022 Introduction. Extramedullary sites of leukemic proliferation, harboring an adverse outcome, are rare and usually found in the blastic phase of chronic myeloid leukemia.
Sekulić Borivoj +4 more
doaj +1 more source
The Relationship Between the Type of bcr-abl Hybrid Messenger RNA and Thrombopoiesis in Philadelphia-Positive Chronic Myelogenous Leukemia [PDF]
Leukemia & Lymphoma, 1993 Formation of the Philadelphia (Ph1) chromosome, which contains the hybrid bcr-abl gene, is thought to be the initial event in chronic myelogenous leukemia (CML). The positions of the breakpoint within the breakpoint cluster region (bcr) on the bcr-abl gene in 22 chronic-phase cases of Ph1-positive CML were determined using conventional Southern blots ...
K, Inokuchi, T, Nomura
+8 more sources
Hematology, Transfusion and Cell Therapy, 2022 Introduction: Treatment-free remission (TFR) is a new goal of chronic myeloid leukemia (CML) therapy. TFR is feasible when the patient has achieved a deep and stable molecular response and met the criteria required to ensure its success.
Carla Boquimpani +8 more
doaj +1 more source